Decrease in SinglePlex Viral PCRs Use and acyclovir utilization following implementation of The BioFire Meningitis/Encephalitis Panel at A Tertiary Care Cancer Center [0.03%]
一项三级护理癌症中心实施BioFire脑膜炎/脑炎检测试剂盒后的单重病毒PCR检测使用量及阿昔洛韦利用情况的下降趋势分析
Tracy McMillen,Eleanor Powell,Krupa Jani et al.
Tracy McMillen et al.
Purpose: Meningitis and encephalitis are medical emergencies requiring prompt intervention. The BioFire Meningitis/Encephalitis (M/E) panel (BioFire® Diagnostics, Salt Lake City, UT) is approved by the U.S. Food and Drug...
Comparative evaluation of SARS-CoV-2 serological tests shows significant variability in performance across different years of infection and between the tests [0.03%]
对SARS-CoV-2血清学检测的比较评估显示不同感染年份及不同检测试剂盒之间性能差异较大
Dell-Dylan Kenfack,Georges Nguefack-Tsague,Veronique B Penlap et al.
Dell-Dylan Kenfack et al.
Introduction: While the global COVID-19 pandemic is slowly coming under control, current efforts are focused on understanding the epidemiology of endemic SARS-CoV-2. The tool of choice for doing so remains serological tes...
Detection of coxsackievirus A6 in formalin-fixed, paraffin-embedded skin biopsy specimens using immunohistochemistry and real-time reverse-transcriptase PCR [0.03%]
福尔马林固定石蜡包埋的皮肤活检标本中通过免疫组织化学和实时逆转录PCR检测柯萨奇病毒A6
Amy M Denison,Julu Bhatnagar,Richard R Jahan-Tigh et al.
Amy M Denison et al.
Background: Hand, foot, and mouth disease (HFMD), classically a childhood viral infection, has an atypical and severe clinical presentation in adults. Coxsackievirus A6 is a leading cause of atypical HFMD, but current dia...
SARS-CoV-2 antibody response duration and neutralization following natural infection [0.03%]
自然感染后的新冠病毒抗体反应持续时间和中和作用
Christopher W Dukes,Renata Am Rossetti,Jonathan A Hensel et al.
Christopher W Dukes et al.
Background: The role of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) neutralizing antibody response from natural infection and vaccination, and the potential determinants of this response are poorly un...
Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations [0.03%]
突破性omicron感染可有效增强之前的BNT162b2疫苗接种诱导的抗体反应
Thomas Perkmann,David N Springer,Patrick Mucher et al.
Thomas Perkmann et al.
Objective: To investigate whether SARS-CoV-2 omicron breakthrough infection in individuals after three doses of wildtype-based BNT162b2 increases antibody levels measured by a commercially available wildtype-based immunoa...
High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses [0.03%]
尼日利亚拉各斯高SARS-CoV-2血清阳性率，具有强大的抗体和细胞免疫反应
Sulaimon Akanmu,Bobby Brooke Herrera,Beth Chaplin et al.
Sulaimon Akanmu et al.
Background: Early evidence suggested that the impact of the COVID-19 pandemic was less severe in Africa compared to other parts of the world. However, more recent studies indicate higher SARS-CoV-2 infection and COVID-19 ...
Analysis of SARS-CoV-2 sublineages reported from local cases in mainland China (September 2022-January 2023) and surveillance of outbound passengers [0.03%]
中国大陆（2022年9月-2023年1月）本土新冠肺炎病例报告的新冠病毒变异株分析及出港旅客监测
Daniele Focosi,Federico Gueli,Cesare Gruber et al.
Daniele Focosi et al.
Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients [0.03%]
关于凯斯丽 Vilimab&imid Vilimab、瑞德西韦和法匹拉韦治疗住院新冠肺炎患者的临床研究：一项开放性、随机对照试验
Sahar K Hegazy,Samar Tharwat,Ahmed H Hassan
Sahar K Hegazy
Background: Corona Virus disease - 2019 (COVID-19) disease induces scientific research to find a control to this pandemic from 2020 year up to now. Recently, various advances in pharmacotherapy against COVID-19 have emerg...
When rare becomes common: N2 gene-positive, E gene-negative SARS-CoV-2 PCR results between 2021 and 2022 [0.03%]
从2021年到2022年的N2基因阳性、E基因阴性新冠病毒核酸检测结果
Frank Bernhard Kraus,Stefan Moritz,Könül Mamadova et al.
Frank Bernhard Kraus et al.
Nucleocapsid gene-positive, envelope gene-negative (N2+/E-) SARS-CoV-2 PCR results obtained with the Cepheid Xpert Xpress SARS-CoV-2 assay are an infrequent phenomenon. We assessed the validity of the N2+/E- cases with an indirect approach ...
SARS-CoV-2 evolution during persistent infection in a CAR-T recipient shows an escape to both sotrovimab and T-cell responses [0.03%]
CAR-T细胞治疗患者的持续性SARS-CoV-2感染显示出了对索托维单抗和T细胞反应的逃逸
Paola Mazzetti,Pietro Giorgio Spezia,Anna-Lisa Capria et al.
Paola Mazzetti et al.